Vanguard (NVAX) amends 13G/A, reports 0 shares after Jan 12, 2026 realignment
Rhea-AI Filing Summary
The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Novavax Inc. common stock, representing 0% of the class.
The amendment explains an internal realignment effective January 12, 2026 and states certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does The Vanguard Group report for NVAX ownership?
The filing reports 0 shares beneficially owned, equal to 0% of Novavax common stock. The Schedule 13G/A shows no sole or shared voting or dispositive power over any shares as reported in Item 4.
Why did Vanguard change how it reports NVAX holdings?
Vanguard cites an internal realignment on January 12, 2026, causing certain subsidiaries or divisions to report separately. The amendment relies on SEC Release No. 34-39538 for disaggregated reporting of prior holdings.
Who signed the Schedule 13G/A amendment for NVAX?
The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/27/2026. The signer attests to the reporting information provided in the amendment.
Does the amendment identify any other persons with >5% interest in NVAX?
The amendment states no other person's interest in the securities reported exceeds 5%. It notes Vanguard-managed investment companies and accounts may hold rights to dividends or proceeds but no single outside person exceeds the threshold.